Login
Companies $BAX
$25.54 +$0.00 (0.0%) After hours
BAXTER INTERNATIONAL INC logo

BAXTER INTERNATIONAL INC

baxter.com

What Do They Do?

Sells medical products and therapies, connected-care equipment, and pharmaceuticals to hospitals and other care providers, and to patients at home under physician supervision.

How Do They Make Money?

Hospitals, healthcare distributors and government agencies pay for healthcare products, usually when products are delivered. Baxter also earns money over time from equipment leases, connected-care projects and contract manufacturing services.

revenue
SegmentShareRevenue
Medical Products & Therapies
Sold outright

47%
FY2022: 48%
Healthcare Systems & Technologies
Sold outright

27%
FY2022: 29%
Pharmaceuticals
Sold outright

22%
FY2022: 21%

Who Are Their Customers?

Hospitals, healthcare distributors and government agencies buy healthcare products. Baxter sells through its own sales force and also through independent distributors, drug wholesalers acting as sales agents, and specialty pharmacies or other alternate-site providers.

Do Revenues Turn Into Profits?

Not on paper. It lost $957M in FY2025, but brought in more cash than it spent: $332M of free cash flow.

Operating income, FY2025
−3% of revenue
▼ Turned to a loss vs FY2024 ($14M, 0%)
Net income, FY2025
−9% of revenue
▼ −47% (Loss) vs FY2024 (−$649M, −6%)
Free cash flow, FY2025
3% of revenue
▼ −42% vs FY2024 ($573M, 5%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +5%
vs $2.8B in Q3 FY2025
Net income
▲ Turned profitable
vs −$46M in Q3 FY2025
Medical Products & Therapies share of revenue vs 69.7% in Q3 FY2025
  • Aug 19, 2026 Baxter appoints John Rogers as CFO Anita Zielinski will leave, and CEO Andrew Hider will serve as interim CFO until Rogers starts.
  • Jul 30, 2026 Baxter raises its full-year financial outlook It raised its sales growth and adjusted earnings outlook.

Flat. Revenue was $11.2B in FY2025, about the same as the $12.1B of FY2021.

Exited businesses Baxter's earlier portfolio included dialysis therapies and BioPharma Solutions contract manufacturing. It sold Kidney Care and BioPharma Solutions, removing those businesses from its portfolio.

Revenue over time
Medical Products & Therapies Healthcare Systems & Technologies Pharmaceuticals Kidney Care
$20B$10B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support